<DOC>
	<DOCNO>NCT00535509</DOCNO>
	<brief_summary>Phase II trial Neoadjuvant [ FEC100 ] /Cisplatin-Docetaxel ± Trastuzumab woman express amplified Her2/Neu Locally advance Breast Cancer</brief_summary>
	<brief_title>Phase II Trial NeoadjuvantFEC100/Cisplatin-Docetaxel ± Trastuzumab Women With Over Expressed Amplified Her2/Neu With Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients locally advance breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>